Patents Assigned to Linnet Biopharmaceuticals, Inc.
  • Rutaecarpine derivatives for activating CYP1A2 in a subject
    Patent number: 8669264
    Abstract: The teachings provided herein generally relate to compositions comprising rutaecarpine derivatives that activates CYP1A2 through enzyme induction. The uses for such a derivative can include removing caffeine from a subject, improving sleep, treating insomnia, treating caffeine toxicity, treating caffeine addiction and withdrawal symptoms, and the like. Caffeine is just one example of a substrate that can be removed using the derivatives taught herein, and other examples, including theophylline, are provided herein.
    Type: Grant
    Filed: June 17, 2011
    Date of Patent: March 11, 2014
    Assignee: Linnet Biopharmaceuticals, Inc.
    Inventors: Liang Xue, William K. Chan, Stan W. Linnet, Timothy N. Linnet